Jaguar Health (JAGX) Short-term Investments (2025 - 2026)
Jaguar Health's (JAGX) quarterly Short-term Investments came in at $2.8 million in Q1 2026, down 59.41% on a QoQ basis from $6.9 million in Q4 2025.
Jaguar Health (JAGX) Short-term Investments (2025 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 2 years of Short-term Investments data on file, last reported at $2.8 million in Q1 2026.
- On a quarterly basis, Short-term Investments changed N/A year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.9 million, changed N/A from the prior year.
- Short-term Investments for Q1 2026 stood at $2.8 million, down from $6.9 million in the prior quarter.
- Over the last five years, Short-term Investments for JAGX reached as high as $6.9 million in Q4 2025 and fell as low as $2.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,774.59 Bn | 1,774.53 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.91 Bn | 116.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.79 Bn | 63.04 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - |
| 7 | Argenx Se | 54.75 Bn | 49.57 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.10 Bn | 35.10 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.11 Bn | 36.11 Bn | - |
| 10 | Jaguar Health | 509,443.80 | -9.55 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.79 Mn |
| Dec 31, 2025 | 6.86 Mn |